MCM7 and neoplasm: MCM-7 was evaluated in 70 non-functioning PAs (NFPAs), and it was found that MCM-7 expression was higher in the tumour progression group compared with the stable disease group over 6 years of follow-up (p<0.0001).31 The median MCM-7 expression was 7.4% (interquartile range [IQR] 2.4–15.2) in the group with tumour progression and 2.0% (IQR 0.6–5.3) in the stable disease group.